MedTrace Logo

Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer

NCT00002976 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2108

Last updated 2013-04-11

No results posted yet for this study

Summary

RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence.

PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.

Conditions

Interventions

DRUG

conjugated estrogens

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    collaborator NETWORK

  • SWOG Cancer Research Network

    collaborator NETWORK

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Richard R. Barakat, MD · Memorial Sloan Kettering Cancer Center

  • Scott Wadler, MD · Albert Einstein College of Medicine

  • David S. Alberts, MD · University of Arizona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30
Primary Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002976 on ClinicalTrials.gov